Legend Biotech Corporation (NASDAQ:LEGN) Q2 2023 Earnings Call Transcript

Legend Biotech Corporation (NASDAQ:LEGN) Q2 2023 Earnings Call Transcript August 15, 2023

Legend Biotech Corporation misses on earnings expectations. Reported EPS is $-1.14 EPS, expectations were $0.69.

Operator: Good morning and thank you for standing by. Welcome to the Legend Biotech Reports Second Quarter 2023 Financial Results. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to turn the conference over to Jessie Yeung, Head of Investor Relations and Public Relations. Please go ahead.

Jessie Yeung: Good morning. This is Jessie Yeung, Head of Investor Relations and Public Relations at Legend Biotech. Thank you for joining our conference call today to review our second quarter 2023 performance. Joining me on today’s call are Ying Huang, our CEO; and Lori Macomber, Legend’s CFO. Following the prepared remarks, we will open up the call for Q&A. We have Guowei Fang, Chief Scientific Officer, and Steve Gavel, Head of Commercial Development for the US and Europe joining the Q&A session. During today’s call we will be making forward-looking statements which are subject to risks and uncertainties that may cause our actual results to differ materially from those expressed or implied here within. These forward-looking statements are discussed in greater detail in our SEC filings, which we encourage you to read and can be found under the Investors section of our company website. Thank you and I will now turn the call over to Ying.

Ying Huang: Good morning, everyone. Thank you for joining us today. We have had a very busy first half of the year and we’re excited to be sharing our latest corporate developments with you on a quarterly basis starting with today’s call. Over the past six months, our teams have worked incredibly hard to accomplish a number of critical milestones that have set the stage for decisive growth for our company for years to come. First and foremost, as you may have seen, reported by our partner J&J on July 20th. Our first approved therapy CARVYKTI generated total sales of $170 million in the second quarter of 2023, amounting to a $189 million in sales in the first half of 2023. The strong performance in the quarter exceeded our expectations, which was driven by continued strong demand for our product and a meaningful increase in our daily slot capacity.

We were able to ramp up a lot more quickly than anticipated, and we made continued improvements in our manufacturing processes. We’re very pleased by the progress made in our commercial launch and remain committed to making CARVYKTI available and accessible to patients who are eligible for treatments through our ongoing investments to increase capacity and improve efficiency in the second half of 2023. We continue to find success in our portfolio and pipeline, including the CARTITUDE clinical development program that investigates CARVYKTI in additional patient populations. These results demonstrate the strength of our company and our relentless pursuit of novel therapies for patients with unmet needs. This year, at the American Society of Clinical Oncology meeting in June, we presented new data from our Phase III CARTITUDE-4 study investigating CARVYKTI in relapsed and lenalidomide-refractory patients with one to three prior lines of treatment.

In this study, CARVYKTI reduced the risk of disease progression or death by 74% compared to standard-of-care regimens. The data were also published in the New England Journal of Medicine and presented at the European Hematology Association 2023 Congress later that month. Based on the CARTITUDE-4 data, our partner Janssen submitted a Type II variation application to the European Medicines Agency and a supplemental Biologics License Application to the US Food and Drug Administration to expand the indication for CARVYKTI for use in earlier lines of multiple myeloma treatment as early as after first relapse. We see CARVYKTI as the crux of the new myeloma landscape and have submitted regulatory applications for its expansion from four plus lives to two plus lives.

We’re excited by the potential to provide treatment options to patients earlier in their treatment journey and are encouraged by the results of ongoing CARTITUDE-4 study. We look forward to working closely with regulatory authorities around the world as we seek to expand the indication. As part of our efforts to expand manufacturing capacity, we signed a three-year contract with Novartis to manufacture additional clinical doses of CARVYKTI in April and added additional 35 treatment centers this quarter as part of our ongoing efforts to improve efficiencies, while expanding capacity and access to this novel therapy. In addition to our success with CARVYKTI, we’re also advancing our pipeline of therapies for solid tumors. This quarter, the US Food and Drug Administration branded LB2102 targeting DLL-3, our investigational therapy for small-cell lung cancer and orphan drug designation in which we were able to open a trial site in the US to prepare for patient recruitment.

Another one of our solid tumor programs, LB1908 targeting Claudin 18.2 in gastric cancer is also progressing on track. We recently opened two clinical trial sites in the US for this program in the second quarter and we anticipate dosing our first patient soon. We look forward to reporting on the progress across both of these solid tumor programs in the future. And finally, our financial outlook is equally promising and positions us to execute our plans through 2025. On the heels of our strong CARTITUDE-4 data, we were able to raise approximately $785 million in gross proceeds in the quarter through a registered direct offering, private placements, and the exercise of a warrant, bringing our cash, cash equivalents, deposits and investments to $1.5 billion at quarter-end.

Further, as part of our collaboration with Janssen for CARVYKTI and the CARTITUDE clinical development programs, we received a $15 million milestone payment this quarter, and the acceptance of the Type II application for CARVYKTI and achieved another milestone for $20 million and the US FDA acceptance of the sBLA of CARTITUDE-4. We continue to see additional revenue from CARVYKTI as we reach additional key data and regulatory milestones. Turning to the next slide, slide six, a final analysis of data from the pivotal PhaseIb/II. CARTITUDE-1 study was presented at the ASCO and EHA Annual Meetings this year that showed sustained deep and durable responses in heavily pre-treated patients with relapsed or refractory multiple myeloma. These data show that CARVYKTI continues to demonstrate both efficacy and safety years after treatment, which has made our therapy a leading option for adult patients with relapsed or refractory multiple myeloma.

In addition, five year follow-up data from LEGEND-2 were presented. It is the longest follow-up by any BCMA-targeted CAR-T cell therapy. At the five-year follow-up, these data are encouraging and bolster our belief that cilta-cel or CARVYKTI is a paradigm-shifting therapy. Moving on to slide seven. As I mentioned earlier, we recently announced the submission of the supplemental biologics license application to the US Food and Drug Administration to expand the label for CARVYKTI. The application for expansion includes the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent. With this filing, we hope to move CARVYKTI into the two to four prior lines of therapy setting in multiple myeloma subject to FDA approval.

FDA has now accepted this sBLA filing and assigned a PDUFA date of April 5th, 2024. In the clinic, we plan to complete enrollment of the ongoing Phase III CARTITUDE-5 trial which evaluates cilta-cel in newly-diagnosed patients for whom transplant is not intended by end of this year. Furthermore, we’re planning to initiate enrollment of our first-line CARTITUDE-6 study in fourth quarter of 2023. Next slide, slide eight. We’re pleased to report that CARVYKTI continuous market penetration with net sales of $170 million in second quarter of 2023, consisting of $140 million in the US and $3 million in EU. The 63% quarter-over-quarter sequential growth in the US was primarily driven by high-demand from physicians and patients, higher slot availability and lower out-of-spec rate.

As of June 30, the number of active US treatment sites was 54. One slide nine, you will see our R&D team continues to advance our proprietary pipeline in the second quarter. In last quarter, we opened our first clinical trial site for our DLL-3 program in the US, our second ongoing clinical trial in the US. In addition, a number of patients are being enrolled and dosed in a number of Phase I IIT programs in China. I will now turn the call over to our CFO, Lori Macomber to go over our second quarter financial performance in more detail.

Lori Macomber: Thank you, Ying, and good morning, everyone. As Ying mentioned, we are very pleased with the performance of our commercial product CARVYKTI this quarter, which generated approximately $117 million in total sales, representing a 63% sequential growth and 388% growth over the second quarter of 2022. As a reminder, we share equally in all profits and losses of CARVYKTI ex-China with our partner Janssen. Starting with revenue, total revenues for the second quarter were $73.3 million consisting of $58.2 million in collaboration revenue from the sales of CARVYKTI and $15.1 million in-license revenue for the achievement of a milestone during the quarter, as outlined in the Global Development Plan under the Janssen Agreement for cilta-cel.

Net loss for the three months ended June 30th, 2023, was $199.1 million or a loss of $0.57 per share compared to the net loss of $193.2 million or $0.62 loss per share for the same period last year. For the six months ended June 30th, 2023, net loss was $311.2 million or a loss of $0.91 per share compared to a net loss of $225.5 million or a loss of $0.73 per share for the six months ended June 30th, 2022. Moving onto expenses. Collaboration cost of revenue for the second quarter 2023 was $32.7 million compared to $16.9 million for the same-period last year. These are Legend’s portion of collaboration cost-of-sales in connection with collaboration revenue under the Janssen Agreement along with expenditures to support the manufacturing capacity expansion.

Research and development expenses for the second quarter 2023 were $95.8 million compared to $68.8 million for the same period last year. The increase of $27 million year-over-year is due to higher patient enrollment for Phase III clinical development programs for cilta-cel and increases in R&D activities for our other pipeline programs. Administrative expenses for the three months ended June 30th, 2023 were $27.8 million, compared to $18.1 million for the same period last year. The increase of $9.7 million year-over-year is primarily for the further build-out of administrative functions and continued investment in building our global IT infrastructure along with non-reoccurring financial and legal fees related to the company’s restatement of its historical financial statements.

Selling and distribution expenses for the three months ended June 30th, 2023, was $21.4 million compared to $27.4 million for the same period last year. The decrease year-over-year is primarily due to non-reoccurring launch expenses incurred in the first half of last year to support the US launch of CARVYKTI. To wrap up, our spending remains on track and we continue to maintain a strong balance sheet. As of June 30th, we had $1.5 billion in cash and equivalents, deposits and investments, extending our cash runway through 2025. Thank you. I will now pass it back to Ying for closing remarks.

Ying Huang: Thanks, Lori. In closing, we’re very encouraged by the performance in this year thus far. Our teams continue to execute, making tremendous progress to bring CARVYKTI to more patients while continuing to supply our clinical programs. We have a healthy cash balance to carry out our long range plans across all areas of the business. We now have cash runways sufficient to fund operations throughout 2025. Looking ahead, our priorities include increasing manufacturing capacity, which we will do by continuing to invest in our facilities and working with the FDA to ramp up. Activating more treatment centers in the US and ex-US, progressing our frontline studies across CARTITUDE-5 and 6 studies. Last but not least, advancing our pipeline programs.

We remain steadfast in our commitment to capturing the full potential of CARVYKTI. Our teams across the globe are working tirelessly to enable reliable and consistent product availability to continue with this momentum. I would like to take this opportunity to thank the more than 1500 Legend team members across the globe for their dedication and effort. Before I close the earnings close today, this is a picture of our Obelisk facilities in Ghent, Belgium which we anticipate will be operational for clinical production by end of 2023. We will now open up the call for your questions. Thank you.

Q&A Session

Operator: [Operator Instructions] The first question comes from Kelly Shi with Jefferies. Your line is open.

Kelly Shi: Congrats on the progress and thank you for taking my questions. My first question is regarding the out-of-spec rate. I’m curious, is Legend expecting higher project specification limit, when CARVYKTI gets approval earlier lines from second to fourth line. And should we expect out-of-spec rate improve accordingly for this early line products? Thank you.

Ying Huang: Hey, Kelly. Thanks for the question. So this is Ying. I’m going to answer your questions about out-of-spec. First of all, after all the work we have done in the last six to 12 months, we’re very happy to report that today our current out-of-spec rate is trending down continuously and very close to the labor rate and not much really higher than our competition out-of-spec rate. So we’re happy, we have made a lot of progress over there. Thanks to the effort from our Legend operations teams. And then secondly to answer your question about the widening spec through the CARTITUDE-4 application. We did submit in our sBLA package to the FDA when we filed in June that a comprehensive correlated analysis that provides data to convince the agency we believe to widen our spec pending FDA approval, so if we do get a wider spec from the agency, when we received the CARTITUDE-4 approval on the label.

We expect out-of-spec rate should be down another meaningful months from the current out-of-spec rate here.

Kelly Shi: Thank you very much and I also have —

Ying Huang: So perhaps we have made a lot —

Kelly Shi: Sorry. Go ahead.

Operator: Please standby for the next question. The next question comes from Terence Flynn with Morgan Stanley. Your line is open.

Terence Flynn: Great. Thanks so much for taking the questions maybe two for me. I was just wondering if you can comment at all about the cadence of slots in the second half of the year. If we should still expect an increase there or is it more steady state until 2024? And then my second one relates to the ASH Conference obviously always a big event in myeloma. Just wondering if you could give us a preview of any potential data that you guys might plan on submitting. Thank you.

Operator: Standby for one moment please. Please standby.

Lori Macomber: Hi, Terence. So this is Lori. Thank you for the question. So the cadence that you’re going to see for the second half of the year, you will see a step up from Q2. We — as you know, we got the capacity ramp in Q2, but we didn’t realize that for a full quarter. So you will see somewhat of a step-up in Q3 and then in Q4 we’ll continue with that ramp. Regarding the ASH question, I’ll turn that over to Ying.

Ying Huang: Hey, Terence. Thanks for the questions. So consistent with J&J disclosure policy, we do not really comment on submitted abstracts. But I think given the CARTITUDE-4 data the initial presentation was made at ASCO and EHA. You should probably expect some more subgroup analysis coming from CARTITDE-4. Other than that stay tuned until the ASH abstracts are published. Thank you.

Operator: Please standby for the next question. The next question comes from Gena Wang with Barclays. Your line is open.

Gena Wang: Thank you for taking my questions. The first question is regarding the manufacturing the — between the balance — the balance between clinical trial enrollment versus commercial patient. So just wanted to make sure the Belgian site since active by the year-end ’23, we’ll CARTITUDE-6 manufacturing would be or at the Belgian site initially and then you would move to Novartis sites by second half 2024. And also regarding current active sites in the US, do you still have a slot limitation for each site. And a quickly another sets of question regarding PDUFA, you announced April 5th, 2024, just want to confirm this is a standard review and you do not expect an AdCom.

Operator: Please standby.

Ying Huang: Good morning, Gena. Thanks for the question. I’ll answer the first and the third and then I’ll ask Steve to answer the second question. So on your first question, yes, we do fully expect our first stage of our Ghent, Belgium, facility to come online by end of this year. And we’re planning to start enrollment for CARTITUDE-6 basically around the timing of the coming up online for our Ghent facility. So we will start clinical production for CARTITUDE-6 from our Ghent facility. I can’t comment on Novartis at this point, but suffice to say, everything is on track at this point in terms of tech transfer and related activities. And then on your third question on PDUFA dates, yes, I can confirm that the PDUFA date is April 5th, 2024, under standard review. Steve?

Steve Gavel: Yes. Thanks. Yes, so the question had to do with allocation for sites. So you’re correct. So we launched on an allocated model here in the US. And we continue to be in an allocated model for the foreseeable future. However, what we did do recently as our out-of-spec continue to have significant improvements. We also added a pool concept into the US. We have additional slots that our sites can then go into providing they have, obviously, that level of patient demand. So right now, in the US, we have a bit of a hybrid where we have all sites being allocated as well as an open pool approach for some specific sites within the US.

Operator: Please standby for the next question. The next question comes from Umer Raffat with Evercore. Your line is open.

Umer Raffat: Hi, guys. Thanks for taking my question. Ying, first, can you remind us what’s going on with the Board dynamics and GenScript and what changes may or may not be happening? If we can just understand what’s happening on the Board front and governance front. Secondly, I know you have a DLL-3 CAR-T in your Phase I right now. Can you remind us, a) what did we learn from the DLL-3 CAR-T failure at Amgen? This is a 2019 program. And also what was the lag between when your IND was filed or cleared back in fall last year versus about seven or eight months it took to actually get the first patient recruited? Thank you very much.

Operator: Please standby.

Ying Huang: Hi, Umer. Thanks for the questions. This is Ying. So I’ll answer first about the board. As you know, we have a ten-member board and our shareholder GenScript actually has appointed three board members. And this is consistent with the 48% equity ownership held by GenScript. I think the Board is very productive because we do have a good mix of independent board members, six of those, and one representative from the company and three from our sizable shareholder GenScript. So I think in terms of board dynamics, it’s a pretty good mix between a large shareholder and the six independent board members. And as you can tell, in terms of CARVYKTI and the CARTITUDE programs as well as our pipeline, the company is doing very well in terms of advancing on both fronts. And that is under the guidance of the Board of Directors. So that’s the first question. And what was your second question, Umer?

Umer Raffat: My second question was around the DLL-3 CAR-T project?

Guowei Fang: This is Guowei Fang. Yeah, I can comment on the second question that is, with regard to the Amgen’s DLL-3 targeted CAR-T therapy. As we know that Amgen has two different DLL-3 target product in clinical trial. And one of them was autologous CAR-T therapy. Second one is DLL-3 targeted CD3 bispecific. Further, I’ll talk about CAR-T product. We tried in several patients in the second dose cohorts. They tested in two patients. One patient actually gave a very durable response. Based on Amgen’s communication, their decision on stopping the autologous CAR-T product development is solely based on their portfolio prioritization. They’ve decided to focus on the DLL-3 CD3 bispecific antibody. We think that the DLL-3 targeted autologous CAR-T therapy could provide substantial benefits to the patient.

First, from a disease perspective, this is a disease of highly — with highly unmet medical need, from the targeted perspective, this is also an ideal target for autologous cell therapy in solid tumor indications, as we know that DLL-3 is a specific biomarker for neuroendocrine cell damage. And in this aspect is very similar to some of the very successful CAR-T target in blood cancer. All of them targeting that each specific biomarker. Our design of the DLL-3 product is quite different from Amgen’s product. First, we have a unique CAR design in terms of binder, in terms of overall architecture of the cost structure. Secondly, adding a unique armor mechanism. And currently this program is R&D — being created by our R&D and we have two side activities and we are actively be moving the program forward.

Ying Huang: And, Umer, this is Ying, maybe I want to add the fact that you probably have noticed this, DLL-3 is the first-ever IND and clinical program we moved into the US without conducting a first-in-human study in China. So we do believe that the competitive data in DLL-3 from Amgen actually shows very promising data from the Phase II recently. And I think that’s somewhat clinically validated target. That’s why we decided to bring this study into IND at risk. Thank you.

Operator: Please stand by for the next question. The next question comes from Yaron Werber with Cowen. Your line is open.

Yaron Werber: Hi, good morning, and thanks for taking my questions as well. So, Ying, it’s a little bit about we’re seeing from some of your competitors that they had extra capacity for CAR-T in Q2 and it looks like it was demand-driven exactly when you ramped up both your out-of-spec and your overall capacity. Can you talk a little bit what is your demand backlog looking like? Are you still seeing more demand than you actually have supply? And what are you seeing from TECVAYLI and now TALVEY as they’re coming to the market? Have you seen any impact on your demand? And how is J&J going to position, just sequencing-wise? Thank you.

Operator: Please stand by.

Ying Huang: Yaron, thanks for the question. I’ll ask my colleague Steve to answer this question. Steve?

Steve Gavel: Yes, thanks, Ying. Hi, Yaron. Yes, we’ve seen just the opposite, especially coming out of ASCO with release of the CAR-4 data. We’ve done a lot of research as you can imagine in this space. And market demand has done nothing but increase for cilta-cel. So in terms of your question, in terms of the backlog that we’re seeing, we have seen a reduction for sure since launch in terms of the queue, especially in the later-line population and that’s been largely driven to the fact of, like you mentioned, there has been a bispecific entry into market. But mostly, on our front, it’s just in the near term or I should say when we launched, our inability unfortunately to meet that demand out of the gate. But for sure, we are not seeing any lessening at all in demand in these late lines of treatment in particular and just the opposite in these earlier lines of treatment, should we get this indication second line plus, demand there has been very strong, especially in the high risk population.

Ying Huang: And maybe I want to add Yaron that I talked to our Head of Technical Operations, very frequently. I can confirm that starting from January of this year. We have not seen any meaningful change at all in our backlog, in terms of the backlog for our manufacturing operation to process.

Steve Gavel: I think there was a second question knowing on that around bispecifics, I didn’t — I didn’t. Yes, so let me just address that. So I think the question had to do what’s happening with the bispecifics in market and also I think it was a question related to Janssen. So what we’re seeing very clearly around the bispecifics is as a bridge to get to the CAR-T therapies. Again, it’s in reaction to our manufacturing constraints that we’re working under. So for sure, and this is a good situation, obviously for patients to be able to bridge to a CAR-T therapy i.e., cilta-cel in bridging from whatever that bispecific maybe you’ve seen recently a number of bispecific being approved. Again, this is a very good situation for patients have these different options, and also most importantly I think this is a very key point is that the commercial insurers in the US continue to reimburse for CAR-T therapy once a bispecific or if a bispecific is used prior to cilta-cel.

So with that again speaks to the overwhelming efficacy that we’re seeing for this program, even when a prior BCMA therapy is used.

Operator: Please standby for the next question. The next question comes from Leonid Timashev with RBC Capital. Your line is open.

Leonid Timashev: Hi, guys. Congrats on the progress and thanks for taking my question. I guess going back to the priority review and the potential launch in the second and fourth line. I guess any impacts to the launch timing and readiness or will you be able to create a backlog of loss for the second to fourth line launch as well. And then I guess related to that, what are you hearing on the ground about how physicians are thinking about using CARVYKTI when it becomes available in this second to fourth line indication, are they going to slowly move up starting the fourth line and third line or would you expect them to jump straight to second line given the strength of the data which might potentially require more supply? Thanks.

Steve Gavel: Yeah. Hey, Leo. Excuse me, it’s Steve. Why don’t I go ahead and answer your question. It’s the right question, right. So what the — what our models are showing and what the research is showing and I mentioned this in the earlier response I just made is in particular in the high risk population, we’re seeing very quick adoption regardless of line of therapy, right. So — and I’m sure you’re probably working your models, in particular in the second line setting, in particular, we noticed between anywhere between 15% to 20% of that second line population is deemed to be at high risk. Our research is telling us very clearly based on the data we presented, that is a population that our physicians in the US is that the very much of a treatable population for cilta-cel.

And that’s how we’re modeling this as well, as you go in later lines of therapy, you see more aggressive use of cilta-cel. So that’s how we are modeling from our perspective, but you will see across the board use for this product. And like you said, in particular in the high risk population you’ll see very high use once we have this approval.

Operator: Please standby for the next question. The next question comes from Kostas Biliouris with BMO Capital. Your line is open.

Kostas Biliouris: Congrats on the progress and thanks for taking our questions. A couple of questions from us. The first one for Lori, in the first quarter of 2023, ABECMA generated US sales, which was similar to your sales in the second quarter of 2023. Given that ABECMA was a profitable product in the first quarter of 2023. Can you discuss your timeline to profitability? And the second question is BMS and 270 Bio announced recently a maintenance at one of their manufacturing site which has likely impacted the revenues. I was wondering will you also need this type of maintenance at your manufacturing sites and how frequently would you need that, if at all? Thank you.

Lori Macomber: Hi, Kostas. How are you doing? So regarding the question of our sales and profitability. As you know, we’ve been steadily ramping up and as our volumes have been increasing our profitability, particularly in our gross margin is improving. Overall from a collaboration standpoint as you know, we’re continuing to make significant investments into the frontline clinical trial studies of bulk manufacturing capacity. So from a program standpoint, it will still be a while before we see overall profitability for the program. But as you saw in Q2 we’re making significant strides on the gross margin side. Regarding the second question, I’m sorry can you repeat the second question.

Kostas Biliouris: The second question has to do with the maintenance. So 270 Bio and BMS per quarter maintenance at one of their ABECMA manufacturing sites and this slowed down the production and impacted. The revenues of ABECMA, I was wondering whether you will also need to perform maintenance at your manufacturing sites, at some point for CARVYKTI and how frequently would you need that, if at all? Thank you.

Ying Huang: Hey, Kostas. This is Ying. I’ll take this part of the question from you on maintenance. So as you know, for any aseptic GMP manufacture every year you are required by FDA to do this kind of maintenance. However, our operation from the Janssen and Legend teams in New Jersey, we have decided to take a very smart approach which is, we’re not going to shutdown facility at all. Instead, we’ll do a rotation from all the different suites. So, yes, every six months, we will have to do the so called aseptic simulation run. But it really wouldn’t affect the revenues so much that you’re going to see quarter-over-quarter decrease here. So we are planning for this margin and we will obviously conduct all the required aseptic processes for the rest of the year. But suffice to say, we’re not planning a shutdown of the facility just to confirm. Thank you.

Kostas Biliouris: Thank you. Very helpful.

Operator: Please standby for the next question. The next question comes from Justin Zelin with BTIG. Your line is open.

Justin Zelin: Hi. Congrats on the progress and thanks for taking the question. Maybe for Steve, so just assuming you get approval in the earlier lines here. Maybe you could help us understand how slots will be prioritized, whether the line of therapy will make an impact here or whether the high risk patients may be prioritized for slots. And if you could just also comment on outpatient administration. Thank you.

Steve Gavel: Yeah. Hey, Justin. Yeah, in terms of a slot priorities or slot prioritizations. So a couple of things just to kind of maybe rewind in terms of how we allocate and how things happen, but what happens at the site. So we will make our allocations. And as I mentioned to you as capacity increases we’ll actually be allocating higher amounts as well as increasing what we call this open pool for all sites to get into. In terms of what types of patients and the allocation in terms of patient type, in terms of who gets what slot, that is basically driven at the site. I know the sites now have different criteria that each of these sites are using in terms of — who will be getting cilta-cel and other therapies, so that will be driven at the site level not at our end.

In terms of, I think I get a question on outpatient, thanks for that question, right. So for those of you who’ve been following us for quite some times, know that that’s an important dynamic as we get more larger and larger indications for this therapy. So what we’re seeing and this is interesting, we’ve seen our quarter-over-quarter quite a bit of an increase in outpatient use, we’ve seen in the first quarter for cilta-cel about 18% of the claims that we’ve analyzed have shown about 18% of the time that these patients are being treated in an outpatient clinic within the hospitals. Now for the second quarter, we are seeing quite a bit of a jump now up to 30%. So you’re seeing this really dynamic move from inpatient to outpatient for CAR-T therapy, which is exciting for a number of reasons, especially for patients and also keeping cost down.

But also the follow-up question you might have is what’s happening with the marketplace, our competitor you’re seeing less than 10% of the time, our competitor is actually being used in the outpatient setting. So for sure, we believe we have more operational flexibility with cilta-cel and more importantly, now you’re starting to see this play out in the market and we believe that’s again benefits everyone, most importantly the patient.

Justin Zelin: Excellent. Thanks for taking the questions.

Operator: Please stand by for the next question. The next question comes from Mitchell Kapoor with H.C. Wainwright. Your line is open.

Mitchell Kapoor: Hi, everyone. Thanks for taking the questions. Firstly I just wanted you to comment broadly on the out-of-spec rate when this could virtually not be an issue anymore. And then secondly, if you could just comment on the earlier pipeline the catalysts and timelines, we could expect for the next 12 to 24 months. Thank you.

Ying Huang: Hi, Mitchell. Thank you for your question. This is Ying. So on out-of-spec, I’ll quote one industry example, which is the Kymriah and Novartis, right. There’s a paper out there in the public demand that describes originally the OS rate was probably in the high 20s or 30s, but then after about one to two years of improvement in workstream, Novartis was able to reduce that to now about 2%. So obviously, this can be done and also from our own experience the Janssen and Legend teams work really hard in the last year also and we were also able to see a very meaningful and significant reduction in our OS from the beginning of the launch to now in the teens. And we continue to optimize our work stream and there’s a lot of work we can do.

As I mentioned previously in this call, we have submitted a lot of data to the agency as part of the sBLA and we do expect that we can get a wider release back from the agency on the CARTITUDE-4 data. So when that happens, we expect a very meaningful reduction in the out-of-spec rate. And eventually our goal is to reduce that to low single-digit, low to middle single-digit out-of-spec rate. So that’s our expectation, that’s what we’re working towards too. On your second part of your question in terms of the next 6 to 12 months, obviously, our first priority is to get the FDA approved increasing our capacity, we’re planning for another one by end of this year and then we plan to launch the second line indication depending on the FDA approval by our only PDUFA date of April 5th, 2024.

And we continue to work in terms of increasing the number of facilities that’ll supply CARVYKTI. So we’re doing expansion work in Raritan, and we expect the capacity from Raritan will meaningfully increase in ’25. And then we’re opening up our first stage of Belgium facility in Kent. By end of next year our large Greenfield facility will be also coming online from Kent. And as you know, we’ve been working with third-party CMO to expand our network. So all this effort will crystallize into a much higher capacity in the next couple of years. And we have said previously that we aspire to come up with an annual capacity of 10,000 doses or more by end of 2025. We’re very much on track to achieve that goal at this point given our progress in the construction and also the other funds.

So that’s probably what’s really the most important catalyst or priorities for us in next 6 to 12 months.

Mitchell Kapoor: Thank you.

Operator: Please standby for the next question. The next question comes from Sami Corwin with William Blair. Your line is open.

Brooke Schuster: Hi. Thank you for taking my question. This is Brooke Schuster on for Sami. We are wondering if you could provide any color on reimbursement. And if you saw any challenges in security reimbursement like in comparison to inpatient versus outpatient or the academic versus community setting.

Steve Gavel: Hi, Brooke. It’s Steve again. The short answer is no. The — as of to-date, cilta-cel has really enjoyed quite open access from a reimbursement — reimbursement perspective. And as we lead into the second line plus indication, all indications are very positive. As a matter of fact, when you look at the value — value capture modeling that we’ve done insurers love drug a like cilta-cel because of the potential it has in terms of cost containment potentially long-term cost reduction. So no really right now we’ll continue to monitor that area, obviously, it’s very important one for us. But to date, our reimbursement has not been a problem we don’t foresee any problems in the future.

Brooke Schuster: Thank you.

Operator: Please standby for the next question. The next question comes from Kelsey Goodwin with Guggenheim. Your line is open.

Kelsey Goodwin: Hey, guys. Good morning and thanks for taking my question. I guess first I saw on CARTITUDE-4 the median time from apheresis to cilta-cel infusion was 79 days, I guess what are you seeing in the commercial setting? And what can be done to speed that up? And then separately, maybe building off that last question, could you maybe just provide more color on what you’re seeing in terms of communication mix and referrals from the community? Thanks so much.

Steve Gavel: Sure. I’ll take the question around the commercial cycle time that you referenced. We’re seeing the cycle time from receipts release anywhere between four to five weeks on average, which is I think is fairly consistent to what you’re seeing in market today with most CAR-T therapies. I think there’s a second question, I might refer over to Ying.

Ying Huang: Hi, Kelsey. Thanks for the question on CARTITUDE-4. So, yes, I can confirm that the median time was 79 days cycle time in terms of end-to-end. There are two drivers behind that. Number one is that if you look at the trial sites, we opened for CARTITUDE-4, the large majority, I believe, about 75% to 80% at least from CARTITUDE-4 were enrolled in Europe and the other international regions outside of the US. So if you recall, that was actually conducted during the peak of COVID outbreak. That contribute significantly to the cycle time, because we had to clear the customs and also unfortunately supply chain was severely disrupted during the COVID outbreak. That’s really the major driver behind that. And then secondly, obviously, if you look at the protocol right, there’s all this bridging therapy and the requirement of the standard of care, which is either PVD or [Technical Difficulty].

So that’s really the another reason — a reason why we see a higher than normal cycle time from end-to-end for CARTITUDE-4. But as you just heard from Steve, right. Today during our commercialization in the US, we can confirm that the typical, the receipt to release time is about 35 to 40 days in spec samples. And we continue to make improvement on that and we hope that we can report the shorter end to end time in the next quarter. Thank you.

Operator: I show no further questions at this time. This concludes today’s conference call and thank you for participating. You may now disconnect.